| Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? | |
| | |
MedLine Citation:
|
PMID: 22272701 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Development of the novel topoisomerase II inhibitor, amonafide, began almost 40 years ago. The drug was selected for further investigation owing to evidence of marked antineoplastic efficacy in preclinical models of cancer. When its usefulness in the treatment of various solid malignancies proved limited, focus was shifted to establishing its use as an antileukemic agent, specifically against secondary and treatment-associated acute myeloid leukemia (AML). While Phase I and II studies gave rise to hopes that amonafide might hold the key to treating older patients, including those with multidrug resistant, cytogenetically unfavorable secondary and treatment-associated AML, when used in combination with cytarabine, it failed to demonstrate a survival advantage over standard-of-care therapy in randomized studies. This article will outline the development of amonafide from the laboratory to the bedside and discuss the potential place that this agent has in the current management of AML. |
| | |
Authors:
|
Ciara L Freeman; Ronan Swords; Francis J Giles |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of hematology Volume: 5 ISSN: 1747-4094 ISO Abbreviation: Expert Rev Hematol Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101485942 Medline TA: Expert Rev Hematol Country: England |
Other Details:
|
Languages: eng Pagination: 17-26 Citation Subset: IM |
Affiliation:
|
Mayo Clinic Phoenix Campus, Department of Hematology & Oncology, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA. freemanciara@yahoo.co.uk. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocell...
Next Document: Rasburicase for the treatment of tumor lysis in hematological malignancies.